SCHEMBL6256201

SCHEMBL6256201

[c]1oc2ccccc2c1-c1cccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
ALDH1A1 P00352 6/20 0.44
HPGD P15428 5/20 0.44
HSD17B10 Q99714 5/20 0.44
KDM4E B2RXH2 5/20 0.44
GAA P10253 2/20 0.44
NISCH Q9Y2I1 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37
MAPK1 P28482 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TSHR P16473 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
TP53 P04637 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37
RELA Q04206 1/20 0.37
ATM Q13315 1/20 0.37
SLC6A3 Q01959 1/20 0.36
ALOX15 P16050 2/20 0.36
NPC1 O15118 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2586684 0.91 HPRT1 (0.47) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL5984762 0.85 IKBKE (0.44) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL11728712 0.78 AKR1C3 (0.42) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL7972358 0.78 CYP2A6 (0.38) ALDH1A1HPGDSMN1; SMN2TP53NPC1
SCHEMBL28855694 0.75 TYMP (0.40) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL2958656 0.72 CA1 (0.36) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL9867507 0.72 KDM4E (0.39) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL1018789 0.71 ALOX5 (0.46) MAPTALDH1A1HPGDHSD17B10KDM4E
SCHEMBL5814878 0.70 CHRM2 (0.40) MAPTALDH1A1HPGDKDM4ETDP1
SCHEMBL7980848 0.70 MAOB (0.31) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013070655-A1 METHOD OF INCREASING THE PERFORMANCE OF CATIONIC FABRIC SOFTENERS THE DIAL CORPORATION (US) 2013-05-16 WO claimed
EP-1284257-B1 Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter PFIZER PROD INC (US) 2005-10-05 EP disclosed
US-6784299-B2 CARBOCYCLIC ETHERS SUCH AS (METHYL-(3-(4-PHENOXY-PHENOXY)-3-PHENYL-PROPYL)-AMINO)-ACETIC ACID, USED AS NEUROTRANSMITTER ANTAGONISTS, FOR PROPHYLAXIS OF PSYCHOLOGICAL DISORDERS PFIZER INC. 2004-08-31 US disclosed
EP-1406861-A1 SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT Pfizer Products Inc. (US) 2004-04-14 EP disclosed
US-6710071-B2 SUCH AS ((3-4-(DIFLUORO(PHENYL)METHYL)PHENOXYL-3-PHENYLPROPYL)METHYLAMINO)ACETIC ACID; FOR THE ENHANCEMENT OF COGNITION AND THE TREATMENT OF SCIZOPHRENIA AND OTHER PSYCHOSES PFIZER INC 2004-03-23 US disclosed
US-20030208081-A1 Substituted aromatic ethers as inhibitors of glycine transport PFIZER INC. 2003-11-06 US disclosed
US-6566550-B2 Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders PFIZER INC 2003-05-20 US disclosed
US-20030045569-A1 Difluoromethylene aromatic ethers as inhibitors of glycine transport PFIZER INC. 2003-03-06 US disclosed
EP-1284257-A2 Difluoromethylene aromatic ethers and their use as inhibitors of the glycine type-1 transporter Pfizer Products Inc. (US) 2003-02-19 EP disclosed
US-20030013887-A1 Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders PFIZER INC. 2003-01-16 US disclosed
WO-2003000646-A1 SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT PFIZER PRODUCTS INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013887-A1 Such as (methyl-(3-phenyl-3(4-(3-trifluoromethylphenoxy) phenoxy)propyl)amino)acetic acid for treatment of mental disorders SLC1A2, SLC1A1, SLC1A3 MAPT 797/4885ALDH1A1 1330/4885HPGD 2163/4885
US-20030045569-A1 Difluoromethylene aromatic ethers as inhibitors of glycine transport SLC1A2, SLC1A1, SLC1A3 MAPT 883/4885ALDH1A1 1745/4885HPGD 2941/4885
US-20030208081-A1 Substituted aromatic ethers as inhibitors of glycine transport SLC1A2, SLC1A1, SLC6A1 MAPT 665/4885ALDH1A1 2156/4885HPGD 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.